Search

Your search keyword '"Dupuis, L. Lee"' showing total 668 results
Start Over Author "Dupuis, L. Lee"
668 results on '"Dupuis, L. Lee"'

5. Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update

Author

Patel, Priya, Robinson, Paula D., Fisher, Brian T., Phillips, Robert, Morgan, Jessica E., Lehrnbecher, Thomas, Kuczynski, Susan, Koenig, Christa, Haeusler, Gabrielle M., Esbenshade, Adam, Elgarten, Caitlin, Duong, Nathan, Diorio, Caroline, Castagnola, Elio, Beauchemin, Melissa P., Ammann, Roland A., Dupuis, L. Lee, and Sung, Lillian

Published
2024
Full Text
View/download PDF

9. Guideline for the management of fatigue in children and adolescents with cancer or pediatric hematopoietic cell transplant recipients: 2023 update

Author

Patel, Priya, Robinson, Paula D., van der Torre, Patrick, Tomlinson, Deborah, Seelisch, Jennifer, Oberoi, Sapna, Morgan, Jessica E., Hinds, Pamela S., Götte, Miriam, Gibson, Faith, Duong, Nathan, Davis, Hailey, Culos-Reed, S. Nicole, Cataudella, Danielle, Miranda, Vanessa, Dupuis, L. Lee, and Sung, Lillian

Published
2023
Full Text
View/download PDF

10. Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis

Author

Patel, Priya, Robinson, Paula D., Wahib, Nora, Cheung, Patrick, Wong, Thomas, Cabral, Sandra, Parker, Arden, Cohen, Marie, Devine, Katie, Gibson, Paul, Holdsworth, Mark T., Neumann, Eloise, Orsey, Andrea, Phillips, Robert, Spinelli, Daniela, Thackray, Jennifer, van de Wetering, Marianne, Woods, Deborah, Sung, Lillian, and Dupuis, L. Lee

Published
2022
Full Text
View/download PDF

12. Identifying clinical practice guidelines for the supportive care of children with cancer: A report from the Children's Oncology Group

Author

Seelisch, Jennifer, Sung, Lillian, Kelly, Michael J, Raybin, Jennifer L, Beauchemin, Melissa, Dvorak, Christopher C, Kelly, Katherine Patterson, Nieder, Michael L, Noll, Robert B, Thackray, Jennifer, Ullrich, Nicole J, Cabral, Sandra, Dupuis, L Lee, and Robinson, Paula D

Subjects
Paediatrics, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Pediatric Research Initiative, Cancer, Pediatric Cancer, Clinical Research, Rare Diseases, Clinical Trials and Supportive Activities, Pediatric, Hematology, Good Health and Well Being, Child, Health Services Needs and Demand, Humans, Neoplasms, Palliative Care, Practice Guidelines as Topic, Practice Patterns, Physicians', pediatric cancer, practice guidelines, supportive care, systematic review, Clinical Sciences, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Providing evidence-based supportive care for children with cancer has the potential to optimize treatment outcomes and improve quality of life. The Children's Oncology Group (COG) Supportive Care Guidelines Subcommittee conducted a systematic review to identify current supportive care clinical practice guidelines (CPGs) relevant to childhood cancer or pediatric hematopoietic stem cell transplant. Only 22 papers met the 2011 Institute of Medicine criteria to be considered a CPG. The results highlight the paucity of CPGs available to pediatric oncology healthcare professionals and the pressing need to create CPGs using current methodological standards.

Published
2019

14. Vomiting in children and adolescents receiving intravenous pegaspargase: a retrospective study.

Author

Brown, Jamie M., Mathew, Sherry, Sulis, Maria Luisa, Dupuis, L. Lee, and Thackray, Jennifer

Subjects
CHILD patients, SEROTONIN antagonists, SEROTONIN receptors, EVIDENCE gaps, PEDIATRIC oncology
Abstract

Due to an evidence gap, the emetogenicity of intravenous (IV) pegaspargase was unable to be included in the clinical practice guideline classifying chemotherapy emetogenicity in pediatric patients. This single-center, retrospective chart review describes the proportion of pediatric patients who did not vomit during the acute phase (complete response; CR) after receiving IV pegaspargase and provides an emetogenicity classification using a preexisting framework. Of 44 patients who received IV pegaspargase between 2011 and 2020, 13 received a serotonin receptor antagonist plus dexamethasone or palonosetron alone and all experienced a CR. We, therefore, recommend classifying IV pegaspargase as moderately emetogenic. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Clinical practice guideline‐inconsistent management of fever and neutropenia in pediatric oncology: A Children's Oncology Group study

Author

Dupuis, L. Lee, primary, Fisher, Brian T., additional, Sugalski, A. J., additional, Grimes, Allison Caren, additional, Nuño, Michelle, additional, Ramakrishnan, S., additional, Beauchemin, M. P., additional, Robinson, Paula D., additional, Santesso, Nancy, additional, Walsh, Alexandra, additional, Wrightson, A. R., additional, Yu, Lolie, additional, Parsons, Susan K., additional, and Sung, Lillian, additional

Published
2024
Full Text
View/download PDF

22. Randomized trial of dyadic-report vs proxy-report and self-report symptom assessment for pediatric patients receiving cancer treatments.

Author

Tomlinson, Deborah, Tardif-Theriault, Cassandra, Schechter, Tal, Dupuis, L Lee, and Sung, Lillian

Subjects
CHILD patients, CANCER patients, SELF-evaluation, CANCER treatment, HEMATOLOGIC malignancies
Abstract

Background We validated different approaches to symptom assessment for pediatric cancer patients based on the Symptom Screening in Pediatrics Tool (SSPedi) for self-report (SSPedi and mini-SSPedi), proxy-report (proxy-SSPedi), and structured dyadic-report (co-SSPedi). The objective was to compare co-SSPedi scores vs proxy-report (proxy-SSPedi) and self-report (SSPedi or mini-SSPedi) scores for pediatric patients receiving cancer treatments. Methods This was a single-center, randomized crossover study enrolling English-speaking dyads of pediatric patients with cancer or hematopoietic cell transplant recipients 4-18 years old and their guardians. Dyads were randomized to first complete the dyadic-report (co-SSPedi) or self-report (patients: SSPedi or mini-SSPedi) and proxy-report (guardians: proxy-SSPedi). Dyads then crossed over to the alternate approach. Primary analysis compared total SSPedi scores between randomized groups. Results We enrolled 420 dyads that were randomized to co-SSPedi first (n = 213) or proxy-SSPedi and self-report SSPedi first (n = 207). Mean total SSPedi scores (± standard deviation) were co-SSPedi (9.6 ± 7.1), proxy-SSPedi (9.7 ± 7.5; P  = .950 for comparison vs co-SSPedi), and self-report SSPedi (9.7 ± 8.2; P  = .981 for comparison vs co-SSPedi). Co-SSPedi scores were significantly different from proxy-SSPedi for feeling disappointed or sad, feeling cranky or angry, feeling tired, mouth sores, and changes in taste. Co-SSPedi scores were significantly different from self-report SSPedi scores for problems with thinking or remembering things, feeling tired, mouth sores, tingly or numb hands or feet, and diarrhea. Conclusions Total co-SSPedi scores were not significantly different compared with proxy-report or self-report scores, although there were differences in specific symptom scores. If different reporter types are used during clinical implementation, specifying reporter type will be important. The study was registered at clinicaltrials.gov (NCT #05012917). Symptoms are common and frequently severely bothersome in pediatric patients with cancer and hematopoietic cell transplant (HCT) recipients (1). To measure the extent of bothersome symptoms, the Symptom Screening in Pediatrics Tool (SSPedi) suite of symptom assessment tools was developed for pediatric patients receiving cancer treatments and currently consists of multiple validated instruments. SSPedi was developed for self-report by patients 8-18 years of age (2 , 3). Mini-SSPedi was developed for self-report by patients 4 to 7 years of age (4). Proxy-SSPedi was developed for proxy-report by guardians of pediatric patients 2-18 years of age (5). These 3 instruments can be categorized as either self-report (SSPedi or mini-SSPedi) or proxy-report (proxy-SSPedi). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Supportive Care in Pediatric Oncology: Opportunities and Future Directions

Author

Freedman, Jason L., primary, Beeler, Dori M., additional, Bowers, Alison, additional, Bradford, Natalie, additional, Cheung, Yin Ting, additional, Davies, Maya, additional, Dupuis, L. Lee, additional, Elgarten, Caitlin W., additional, Jones, Torri M., additional, Jubelirer, Tracey, additional, Miller, Tamara P., additional, Patel, Priya, additional, Phillips, Charles A., additional, Wardill, Hannah R., additional, and Orsey, Andrea D., additional

Published
2023
Full Text
View/download PDF

35. Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement

Author

McCune, Jeannine S., Quinones, Christine M., Ritchie, James, Carpenter, Paul A., van Maarseveen, Erik, Yeh, Rosa F., Anasetti, Claudio, Boelens, Jaap J., Hamerschlak, Nelson, Hassan, Moustapha, Kang, Hyoung Jin, Kanda, Yoshinobu, Paci, Angelo, Perales, Miguel-Angel, Shaw, Peter J., Seewaldt, Victoria L., Savani, Bipin N., Hsieh, Angela, Poon, Betsy, Mohty, Mohamad, Pulsipher, Michael A., Pasquini, Marcelo, and Dupuis, L. Lee

Published
2019
Full Text
View/download PDF

36. Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning

Author

McCune, Jeannine S., Wang, Tao, Bo-Subait, Khalid, Aljurf, Mahmoud, Beitinjaneh, Amer, Bubalo, Joseph, Cahn, Jean-Yves, Cerny, Jan, Chhabra, Saurabh, Cumpston, Aaron, Dupuis, L. Lee, Lazarus, Hillard M., Marks, David I., Maziarz, Richard T., Norkin, Maxim, Prestidge, Tim, Mineishi, Shin, Krem, Maxwell M., Pasquini, Marcelo, and Martin, Paul J.

Published
2019
Full Text
View/download PDF

37. Validation of co–Symptom Screening in Pediatrics Tool: a novel dyadic approach to symptom screening in pediatric patients receiving cancer treatment.

Author

Tomlinson, Deborah, Dupuis, L Lee, Dix, David, Crellin-Parsons, Nicole, Cook, Sadie, Kulkarni, Ketan, Schechter, Tal, Tomlinson, George A, and Sung, Lillian

Subjects
*CHILD patients, *MEDICAL screening, *CANCER patients, *CANCER treatment, *CRONBACH'S alpha
Abstract

Background Co-Symptom Screening in Pediatrics Tool (co-SSPedi) is a dyadic (child-guardian) approach to symptom assessment. Objectives were to evaluate the reliability and validity of co-SSPedi for pediatric patients receiving cancer treatments. Methods This multicenter study included dyads of patients aged 4-18 years of age with cancer or undergoing hematopoietic cell transplant and their guardians. Two groups were enrolled. The more symptomatic group included those receiving active treatment for cancer or undergoing hematopoietic cell transplant where patients were in hospital or clinic for 4 consecutive days. The less symptomatic group included those receiving maintenance therapy for acute lymphoblastic leukemia or who had completed cancer treatments. At baseline, all dyads completed co-SSPedi, and guardians completed measures of mucositis, nausea, pain, quality of life, and overall symptoms. In the more symptomatic group, dyads completed co-SSPedi and a global symptom change scale on day 4. Results There were 501 dyads included: 301 in the more symptomatic group and 200 in the less symptomatic group. Median time to complete co-SSPedi was less than 3 minutes in both groups. Test-retest reliability intraclass correlation coefficient was 0.85 (95% confidence interval [CI] = 0.77 to 0.90). For internal consistency, total co-SSPedi Cronbach alpha was 0.81 (95% CI = 0.78 to 0.83). For known groups validation, mean difference in total co-SSPedi scores between the more symptomatic and less symptomatic groups was 7.8 (95% CI = 6.7 to 8.8; P  < .0001). For convergent validation and responsiveness, all hypothesized relationships were demonstrated. Conclusions Co-SSPedi is a novel approach to dyadic symptom assessment that is reliable, valid, and responsive in pediatric patients aged 4-18 years. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Treatment of breakthrough and prevention of refractory chemotherapy‐induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update

Author

Patel, Priya, primary, Robinson, Paula D., additional, Phillips, Robert, additional, Baggott, Christina, additional, Devine, Katie, additional, Gibson, Paul, additional, Guilcher, Gregory M. T., additional, Holdsworth, Mark T., additional, Neumann, Eloise, additional, Orsey, Andrea D., additional, Spinelli, Daniela, additional, Thackray, Jennifer, additional, van de Wetering, Marianne, additional, Cabral, Sandra, additional, Sung, Lillian, additional, and Dupuis, L. Lee, additional

Published
2023
Full Text
View/download PDF

50. Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update

Author

Lehrnbecher, Thomas, primary, Robinson, Paula D., additional, Ammann, Roland A., additional, Fisher, Brian, additional, Patel, Priya, additional, Phillips, Robert, additional, Beauchemin, Melissa P., additional, Carlesse, Fabianne, additional, Castagnola, Elio, additional, Davis, Bonnie L., additional, Elgarten, Caitlin W., additional, Groll, Andreas H., additional, Haeusler, Gabrielle M., additional, Koenig, Christa, additional, Santolaya, Maria E., additional, Tissing, Wim J.E., additional, Wolf, Joshua, additional, Alexander, Sarah, additional, Hu, Helen, additional, Dupuis, L. Lee, additional, and Sung, Lillian, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results